Skip to Content
Accesswire

50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021

RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1x1 meetings with qualified investors throughout the event.

John Hope Bryant, guest host on CNBC and CEO of Operation HOPE will deliver the keynote to kick off the conference on Tuesday, July 13th at 9 am ET. Three educational panels will also take place over the three days at 11 am each day. The panels are as follows:

Tuesday, July 13th, 2021
Panel: ESG
Speakers: Andy Behar, CEO, As You Sow and Dr. Christine Chow, IHS Markit

Wednesday, July 14th, 2021
Panel: Pledge 1% - How Companies & VCs/Investors Can Leverage Equity for Social Impact
Speakers: Jan D'Alesandro, Tim Connors and Jessica Lindl

Thursday, July 15th, 2021
Panel: Human Capital
Speakers: Starla Sampaco, Nihad Karabernou McBride and Georgia Homsany

A live webcast, including audio, video, and presentation slides, will be accessible for registered participants here. Interested parties unable to watch the live webcast will be able to view and listen to an archived copy of the webcast, which will be available here as well following the conclusion of the event.

Join us and gain an understanding and potential trends and key value drivers across a wide array of industries. If you are a qualified investor, register here and pledge to take meetings. If you're new to the investment world, come listen to some presentations, panels, and learn more.

The full agenda can be found here, and the full event website can be found here.

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email Angie Goertz or call 919-228-6240.

Companies registered to date:

OrganizationTickerWebsite
Acer TherapeuticsACERhttp://www.acertx.com
Addex Therapeutics Ltd.ADXNhttps://www.addextherapeutics.com/en/
Agile Therapeutics, Inc.AGRXhttps://agiletherapeutics.com/
Alpha CognitionACOGhttps://www.alphacognition.com/
Altigen CommunicationsATGNhttps://www.altigen.com/
ARCA biopharma, Inc.ABIOhttps://arcabio.com/
Auddia Inc.AUUDhttps://auddia.com/
AYRO IncAYROhttp://www.ayro.com
Basanite IndustriesBASAhttps://www.basaniteindustries.com/
BiomericaBMRAhttps://www.biomerica.com/
BK TechnologiesBKTIhttp://www.bktechnologies.com
Blessed BitesPRIVATEhttps://www.theblessedbites.com/
Blue Star FoodsBSFChttps://www.bluestarfoods.com/
BriaCell Therapeutics CoBCTXhttps://briacell.com/
Brooklyn ImmunotherapeuticsBTXhttps://www.brooklynitx.com/
Data Storage CorporationDTSThttps://www.datastoragecorp.com/
Delcath Systems Inc.DCTHhttp://delcath.com
Diamcor Mining Inc.DMIFFhttp://www.diamcormining.com/
Dolphin Entertainment Inc.DLPNhttps://www.dolphinentertainment.com
Flux Power HoldingsFLUXhttp://www.fluxpower.com
Greenbrook TMS NeuroHealth CentersGBNHhttps://www.greenbrooktms.com/
HAVN Life Sciences Inc. (HAVLF)HAVLFhttps://havnlife.com/
Hollywall EntertainmentHWALhttps://hollywall.com/
Issuer Direct CorporationISDRhttps://www.issuerdirect.com
Issuer PixelPRIVATEhttps://issuerpixel.com/
Item 9 Labs Corp. (INLB)INLBhttps://www.item9labscorp.com/
Know Labs, Inc. (KNWN)KNWNhttps://www.knowlabs.co/
LexaGeneLXXGFhttps://lexagene.com/
Mechanical Technology, IncorporatedMKTYhttps://www.mechtech.com/
Metamaterial, Inc.MMATFhttps://metamaterial.com/
Miravo HealthcareMRVFFhttps://www.miravohealthcare.com/
Nemaura MedicalNMRDhttps://nemauramedical.com/
Nephros, Inc.NEPHhttps://www.nephros.com/
NeuroOne Medical Technologies Corp.NMTChttps://n1mtc.com/
NLS PharmaceuticalsNLSPhttps://nlspharma.com/
Oblong Inc.OBLGhttps://www.oblong.com/
Panbela Therapeutics, Inc.PBLAhttps://panbela.com/
Petros PharmaceuticalsPTPIhttps://www.petrospharma.com/
POSaBIT Systems CorporationPOSAFhttps://www.posabit.com/
Processa Pharmaceuticals, Inc.PCSAhttps://processapharmaceuticals.com/
ProPhase Labs, Inc.PRPHhttps://www.prophaselabs.com/
Protagenic Therapeutics, Inc.PTIXhttps://protagenic.com/
Quality Online Education Group Inc.QOEGhttp://qualityonline.education
Quipt Home MedicalQIPThttps://www.protechhomemedical.com/
Soligenix, Inc.SNGXhttp://www.soligenix.com
Star Equity HoldingsSTRRhttps://www.starequity.com/home
Tego Cyber Inc.TGCBhttps://tegocyber.com
Thunderbird EntertainmentTHBRFhttp://thunderbird.tv/
TraQiQ Inc.TRIQhttps://www.traqiq.com/
Uncommon Giving CorporationPRIVATEhttps://uncommon.today/
Verb Technology CompanyVERBhttp://www.verb.tech
WellteqWTEQhttps://wellteq.co/
Windtree Therapeutics, Inc.WINThttp://www.windtreetx.com

About Access to Giving
Access to Giving is the first-of-its-kind virtual investor conference and will be held July 13th - 15th, 2021. Companies will have the opportunity to tell their story and conduct 1x1's with qualified investors for charity. 100% of monies raised through donations for 1x1 meetings will be given to causes that are focused on financial literacy and financial education.

About Issuer Direct Corporation
Issuer Direct® is an industry-leading communications and compliance company focusing on the needs of corporate issuers. Issuer Direct's principal platform, Platform id. ™, empowers users by thoughtfully integrating the most relevant tools, technologies, and services, thus eliminating the complexity associated with producing and distributing financial and business communications. Headquartered in Raleigh, NC, Issuer Direct serves thousands of public and private companies globally. For more information, please visit www.issuerdirect.com.

Contact Information:
Angie Goertz, Vice President of Events
Issuer Direct Corporation
Office: (919) 228-6240
Email: Angie.Goertz@IssuerDirect.com

SOURCE: Access to Giving - Issuer Direct



View source version on accesswire.com:
https://www.accesswire.com/654764/50-Companies-to-Present-at-the-Access-to-Giving-Virtual-Investor-Conference-on-July-13th--15th-2021

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.